The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Key updates from ASCO GI 2021
Philippe Merle, MD, PhD, Croix-Rousse Hospital, Lyon, France, updates on key trials that wil be presented at this years upcoming American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including the updated overall survival results of the IMbrave150 study (NCT03434379), evaluating atezolizumab and bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
